A phase I trial of recombinant human interferon-γ in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS)

1989 ◽  
Vol 9 (4) ◽  
pp. 351-361 ◽  
Author(s):  
H. Clifford Lane ◽  
Richard T. Davey ◽  
Stephen A. Sherwin ◽  
Henry Masur ◽  
Alain H. Rook ◽  
...  
Keyword(s):  
Phase I ◽  
Acquired Immunodeficiency Syndrome ◽  
Kaposi's Sarcoma ◽  
Phase I Trial ◽  
Kaposi’S Sarcoma ◽  
Interferon Γ ◽  
Human Interferon ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

Multicentric Kaposi's Sarcoma of the Conjunctiva in a Male Homosexual with the Acquired Immunodeficiency Syndrome

Ophthalmology ◽  
1983 ◽  
Vol 90 (8) ◽  
pp. 879-884 ◽  
Author(s):  
Abe M. Macher ◽  
Alan Palestine ◽  
Henry Masur ◽  
Gail Bryant ◽  
Chi-Chao Chan ◽  
...  
Keyword(s):  
Acquired Immunodeficiency Syndrome ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Male Homosexual ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon.

1986 ◽  
Vol 4 (4) ◽  
pp. 544-551 ◽  
Author(s):  
F X Real ◽  
H F Oettgen ◽  
S E Krown
Keyword(s):  
Acquired Immunodeficiency Syndrome ◽  
Kaposi's Sarcoma ◽  
Opportunistic Infections ◽  
Kaposi’S Sarcoma ◽  
Response Duration ◽  
High Dose ◽  
Median Response ◽  
Major Response ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

The efficacy of recombinant leukocyte A interferon (rIFN-alpha A [Roferon-A, Hoffman-La Roche, Nutley, NJ]) treatment of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome was evaluated in sequential trials using high doses (36 X 10(6) units) and low doses (3 X 10(6) units) of interferon. A major response was seen in 38% of patients treated at the high dose, with a median response duration of 18 months. At the low dose, the major response rate was 3%; dose escalation to 36 X 10(6) units resulted in an additional major response rate of 17% in low-dose nonresponders, with a median response duration of 10 months. Four of 11 patients who achieved a complete response remain free of disease, whereas all partial responders have shown disease progression. Unacceptable toxicity occurred in 27% of patients initially treated at the high dose and only in 10% of those who had progressive dose escalation up to 36 X 10(6) units. Prior opportunistic infections correlated negatively with therapeutic response, whereas large tumor burden and gastrointestinal involvement did not. Responding patients showed a significantly longer survival and a lower incidence of subsequent opportunistic infections than nonresponders. However, from our study we cannot determine whether rIFN-alpha A has an effect on the natural history of Kaposi's sarcoma in patients with the acquired immunodeficiency syndrome.

Primary Classic Kaposi's Sarcoma Limited to the Glans Penis (Not Associated with Acquired Immunodeficiency Syndrome)

1992 ◽  
Vol 59 (6) ◽  
pp. 80-83
Author(s):  
M. Guy ◽  
D. Singer ◽  
Y. Arieli ◽  
S. Eisenkfraft
Keyword(s):  
Drug Abuse ◽  
Blood Transfusion ◽  
Acquired Immunodeficiency Syndrome ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Glans Penis ◽  
Adequate Therapy ◽  
Acquired Immunodeficiency ◽  
One Year ◽  
Immunodeficiency Syndrome

We report two cases of primary Kaposi's sarcoma limited to the glans penis. In circumcised men the basic lesion appears as a reddish-violet nodule. The patients denied homosexuality, drug abuse or blood transfusion. Excision of the lesion with wide margins and radiotherapy was adequate therapy. Serological investigations for HIV were all negative. At two years and one year after operation the patients are well with normal serology.

Sign in / Sign up

Export Citation Format

Share Document